A Vision of Accessible Epidemiology

被引：18

作者：

Poole, Charles ^{[1
]}

机构：

[1] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27516 USA

来源：

EPIDEMIOLOGY | 2010年 / 21卷 / 05期

关键词：

APPROVAL PROCESS; CLINICAL-TRIALS; BREAST-CANCER; CARVEDILOL; RISK;

D O I：

10.1097/EDE.0b013e3181e9be3f

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：616 / 618

页数：3

共 19 条

[1] *BRIGH WOM HOSP HA, 2001, CHANN LAB NEWS 2001
[2] *EUR CTR EC TOX CH, 2009, ENH SCI PROC TRANSP
[3] Carvedilol and the Food and Drug Administration approval process:: An introduction
Fisher, LD
Moyé, LA
[J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (01): : 1 - 15
[4] Carvedilol and the food and drug administration (FDA) approval process: The FDA paradigm and reflections on hypothesis testing
Fisher, LD
[J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (01): : 16 - 39
[5] The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer
Gammon, MD
Neugut, AI
Santella, RM
Teitelbaum, SL
Britton, JA
Terry, MB
Eng, SM
Wolff, MS
Stellman, SD
Kabat, GC
Levin, B
Bradlow, HL
Hatch, M
Beyea, J
Camann, D
Trent, M
Senie, RT
Garbowski, GC
Maffeo, C
Montalvan, P
Berkowitz, GS
Kemeny, M
Citron, M
Schnabel, F
Schuss, A
Hajdu, S
Vincguerra, V
Collman, GW
Obrams, GI
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 74 (03) : 235 - 254
[6] HANKINSON SE, 2001, HLTH WOMEN HLTH LIVE, P9
[7] Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors
Hirsch, Laurence
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (06) : 1683 - 1689
[8] *INT SOC ENV EP, GUID ETH REAN REINT
[9] Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Juni, P
Nartey, L
Reichenbach, S
Sterchi, R
Dieppe, PA
Egger, M
[J]. LANCET, 2004, 364 (9450) : 2021 - 2029
[10] End-point interpretation in clinical trials:: The case for discipline
Moyé, LA
[J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (01): : 40 - 49

← 1 2 →